Дата |
---|
07.05.2024 |
06.05.2024 |
03.05.2024 |
02.05.2024 |
01.05.2024 |
30.04.2024 |
29.04.2024 |
26.04.2024 |
25.04.2024 |
24.04.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
1.55
|
1.72
|
1.75
|
1.51
|
1.7687
|
1.60
|
|
|
193 182.54
|
664.00
|
1.43
|
1.72
|
1.78
|
1.70
|
1.89
|
1.72
|
|
|
105 669.98
|
303.00
|
1.71
|
2.08
|
1.70
|
1.70
|
1.87
|
1.72
|
|
|
69 030.12
|
235.00
|
1.70
|
2.00
|
1.94
|
1.73
|
2.13
|
1.79
|
|
|
111 066.29
|
386.00
|
1.80
|
1.95
|
1.84
|
1.71
|
2.0874
|
1.96
|
|
|
137 692.54
|
462.00
|
1.40
|
1.90
|
1.70
|
1.70
|
1.89
|
1.84
|
|
|
67 400.66
|
282.00
|
1.66
|
1.85
|
1.59
|
1.57
|
1.7999
|
1.7301
|
|
|
128 493.26
|
206.00
|
1.59
|
1.88
|
1.60
|
1.56
|
1.73
|
1.59
|
|
|
82 535.41
|
272.00
|
1.40
|
1.77
|
1.61
|
1.6049
|
1.69
|
1.69
|
|
|
42 508.37
|
138.00
|
1.41
|
1.62
|
1.55
|
1.5054
|
1.7106
|
1.66
|
|
|
103 384.54
|
270.00
|
Biofrontera Inc. (Biofrontera) is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions. With a focus on the fields of photodynamic therapy (PDT) and topical antibiotics, Biofrontera currently commercializes the FDA-approved flagship drug Ameluz (aminolevulinic acid hydrochloride gel, 10%) in the United States. When used in combination with PDT and Biofrontera’s BF-RhodoLED lamp, Ameluz-PDT is indicated for the treatment of actinic keratoses (AK), one of the most common precancerous skin conditions. Biofrontera also commercializes the drug Xepi (ozenoxacin cream, 1%), FDA-approved for the treatment of impetigo.
In collaboration with dermatologists, Biofrontera is fully committed to advancing treatment options and patient care.
Показать все Скрыть